Introduction
Preeclampsia is a multisystem disorder of unknown
etiology, commonly presenting with raised blood pressure
(BP) and proteinuria. It is also associated with disturbed
liver function, renal failure, cerebral ischemia, and
abnormalities of the coagulation system [1]. Preeclampsia
and eclampsia complicates 7–10% of pregnancies, leading
to prematurity, IUGR, perinatal asphyxia, and abrubtio
placenta; all of which increase both maternal and fetal
morbidity and mortality.
Magnesium sulfate is widely used in obstetrics and is a
drug of choice in two important complications of
pregnancy, preeclampsia, and preterm labor [2]. Magne-
sium sulfate, which is used to prevent seizures in
preeclamptic patients, also has antithrombotic effects.
However, magnesium sulfate is not a benign drug; it has
been associated with significant adverse drug reactions,
including overdose and the potential for increased blood
loss at delivery [3]. We aimed to observe the effects of
magnesium sulfate on various components of the coagula-
tion system in patients with preeclampsia. We hypothesized
that the systemic effects of magnesium may alter biochem-
ical markers and bleeding time in cases with severe
preeclampsia